<DOC>
	<DOCNO>NCT00569192</DOCNO>
	<brief_summary>The purpose study examine safety efficacy two dos MAP0010 versus placebo asthmatic infant child , 12 month 8 year age , 12-week treatment period .</brief_summary>
	<brief_title>A Study 2 Doses MAP0010 Placebo Asthmatic Children</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male female asthmatic child mild moderate persistent asthma . 12 month 8 year age . For child age 4 8 year : Documented diagnosis asthma least 3 month prior Visit 1 , per NIH ( EPR3 ) criterion . For infant age 12 &lt; 48 month old : 2 wheeze episode past 12 month last &gt; 1 day affect sleep . AND least one major two minor risk factor . Any significant childhood illness/abnormality chronic lung disease Any history upper low respiratory tract infection , within 2 week screen . Any history acute severe asthma attack require ICU admission ventilatory support . Use corticosteroid , include inhale , parental , intranasal , topical corticosteroid within 2 week screen . Any use oral corticosteroid within 30 day screen prolonged use ( &gt; 10 consecutive day ) oral corticosteroid , within 12 week screen .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>asthmatic child</keyword>
</DOC>